$CELZ
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

2024 Q3 Form 10-Q Financial Statement

#000147793224004635 Filed on August 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $8.000K
YoY Change -100.0%
Cost Of Revenue $0.00 $3.200K
YoY Change -100.0%
Gross Profit $0.00 $4.800K
YoY Change -100.0%
Gross Profit Margin 60.0%
Selling, General & Admin $498.6K $676.1K
YoY Change -6.11% -21.34%
% of Gross Profit 14085.13%
Research & Development $581.8K $924.7K
YoY Change -41.39% 198.81%
% of Gross Profit 19265.6%
Depreciation & Amortization $29.27K $29.27K
YoY Change 46.35% 27.15%
% of Gross Profit 609.79%
Operating Expenses $1.110M $1.630M
YoY Change -28.26% 36.75%
Operating Profit -$1.110M -$1.625M
YoY Change -28.09% 36.35%
Interest Expense $69.54K $67.58K
YoY Change -22.73% -24.84%
% of Operating Profit
Other Income/Expense, Net $69.54K $67.58K
YoY Change -22.07% -24.84%
Pretax Income -$1.040M -$1.558M
YoY Change -28.46% 41.34%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.040M -$1.558M
YoY Change -28.46% 41.34%
Net Earnings / Revenue -19471.6%
Basic Earnings Per Share
Diluted Earnings Per Share -$0.75 -$1.11
COMMON SHARES
Basic Shares Outstanding 1.338M shares 1.348M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.260M $7.471M
YoY Change 38.81% 87.28%
Cash & Equivalents $6.260M $7.471M
Short-Term Investments $0.00 $0.00
Other Short-Term Assets $67.61K $129.1K
YoY Change -99.1% -98.67%
Inventory $3.394K $3.394K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $6.331M $7.604M
YoY Change -47.43% -44.64%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.280K $3.280K
YoY Change 0.0%
Total Long-Term Assets $556.5K $385.8K
YoY Change 18.45% -1.8%
TOTAL ASSETS
Total Short-Term Assets $6.331M $7.604M
Total Long-Term Assets $556.5K $385.8K
Total Assets $6.888M $7.990M
YoY Change -44.96% -43.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $273.8K $322.2K
YoY Change -25.41% -6.46%
Accrued Expenses $42.92K $39.92K
YoY Change 7.52% 0.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $330.9K $376.3K
YoY Change -21.43% -5.58%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $330.9K $376.3K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $330.9K $376.3K
YoY Change -21.43% -5.58%
SHAREHOLDERS EQUITY
Retained Earnings -$62.74M -$61.70M
YoY Change 9.26% 10.24%
Common Stock $1.431K $1.431K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $6.557M $7.613M
YoY Change
Total Liabilities & Shareholders Equity $6.888M $7.990M
YoY Change -44.96% -43.45%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$1.040M -$1.558M
YoY Change -28.46% 41.34%
Depreciation, Depletion And Amortization $29.27K $29.27K
YoY Change 46.35% 27.15%
Cash From Operating Activities -$985.6K -$1.469M
YoY Change -24.19% 48.91%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$200.0K $0.00
YoY Change -110.99% -100.0%
Cash From Investing Activities -$200.0K $0.00
YoY Change -110.99% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -25.45K -66.61K
YoY Change
NET CHANGE
Cash From Operating Activities -985.6K -1.469M
Cash From Investing Activities -200.0K 0.000
Cash From Financing Activities -25.45K -66.61K
Net Change In Cash -1.211M -1.536M
YoY Change -332.89% -72.21%
FREE CASH FLOW
Cash From Operating Activities -$985.6K -$1.469M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001187953
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
40000 usd
celz Amortization Expenses
AmortizationExpenses
22970 usd
CY2017Q2 celz Initial Payments To Acquire Intangible Assets
InitialPaymentsToAcquireIntangibleAssets
100000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-53500
dei Entity Registrant Name
EntityRegistrantName
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0622284
dei Entity Address Address Line1
EntityAddressAddressLine1
211 E Osborn Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Phoenix
dei Entity Address State Or Province
EntityAddressStateOrProvince
AZ
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
85012
dei City Area Code
CityAreaCode
480
dei Local Phone Number
LocalPhoneNumber
399-2822
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CELZ
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1338126 shares
CY2024Q2 us-gaap Revenues
Revenues
8000 usd
CY2023Q2 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
8000 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q2 us-gaap Cost Of Revenue
CostOfRevenue
3200 usd
CY2023Q2 us-gaap Cost Of Revenue
CostOfRevenue
0 usd
us-gaap Cost Of Revenue
CostOfRevenue
3200 usd
us-gaap Cost Of Revenue
CostOfRevenue
0 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
4800 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
0 usd
us-gaap Gross Profit
GrossProfit
4800 usd
us-gaap Gross Profit
GrossProfit
0 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
924749 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
309480 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1347141 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
628509 usd
CY2024Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
676086 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
859537 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1347570 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1630557 usd
CY2024Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
29271 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
23021 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
58542 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
46042 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
1630106 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
1192038 usd
us-gaap Operating Expenses
OperatingExpenses
2753253 usd
us-gaap Operating Expenses
OperatingExpenses
2305108 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1625306 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1192038 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2748453 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2305108 usd
CY2024Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
67578 usd
CY2023Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
89913 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
149181 usd
us-gaap Interest And Other Income
InterestAndOtherIncome
151060 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
67578 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
89913 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
149181 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
151060 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1557728 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1102125 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2599272 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2154048 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1557728 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1102125 usd
us-gaap Net Income Loss
NetIncomeLoss
-2599272 usd
us-gaap Net Income Loss
NetIncomeLoss
-2154048 usd
CY2024Q2 celz Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-1.11
CY2023Q2 celz Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-0.78
celz Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-1.84
celz Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
-1.53
CY2024Q2 celz Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
1405208 shares
CY2023Q2 celz Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
1409948 shares
celz Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
1413324 shares
celz Weighted Average Number Of Share Outstanding Basic
WeightedAverageNumberOfShareOutstandingBasic
1408793 shares
us-gaap Profit Loss
ProfitLoss
-2599272 usd
us-gaap Profit Loss
ProfitLoss
-2154048 usd
us-gaap Share Based Compensation
ShareBasedCompensation
18324 usd
us-gaap Share Based Compensation
ShareBasedCompensation
18324 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
58542 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
46042 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3200 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
148160 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
184428 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4878 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2923125 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2366168 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4828379 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
4551049 usd
us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
6520191 usd
us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
5048459 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
6520191 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
497410 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
149514 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
100 usd
us-gaap Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants
ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-149414 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
4004609 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-4330969 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3466867 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8320519 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7471476 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3989550 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
10343796 usd
celz Purchase Of Treasury Stock
PurchaseOfTreasuryStock
-149514 usd
us-gaap Share Based Compensation
ShareBasedCompensation
18324 usd
celz Issuance Of Series B Preferred Stock Amount
IssuanceOfSeriesBPreferredStockAmount
100 usd
us-gaap Net Income Loss
NetIncomeLoss
-2599272 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
7613434 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
9228618 usd
CY2024Q2 celz Purchase Of Treasury Stock
PurchaseOfTreasuryStock
-66718 usd
CY2024Q2 us-gaap Share Based Compensation
ShareBasedCompensation
9162 usd
CY2024Q2 celz Issuance Of Series B Preferred Stock Amount
IssuanceOfSeriesBPreferredStockAmount
100 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-1557728 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
7613434 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
15864674 usd
celz Round Up Shares Issued In Reverse Stock Split Amount
RoundUpSharesIssuedInReverseStockSplitAmount
0 usd
us-gaap Share Based Compensation
ShareBasedCompensation
18324 usd
us-gaap Net Income Loss
NetIncomeLoss
-2154048 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
13728950 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
14821913 usd
CY2023Q2 celz Round Up Shares Issued In Reverse Stock Split Amount
RoundUpSharesIssuedInReverseStockSplitAmount
0 usd
CY2023Q2 us-gaap Share Based Compensation
ShareBasedCompensation
9162 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1102125 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
13728950 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Use of Estimates –</strong></em>The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Concentration Risks</em></strong> – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at <strong>four</strong> financial institutions. As of June 30, 2024, the Company’s balance exceeded the limit at three institutions.</p>
us-gaap Stock Dividends Shares
StockDividendsShares
23502 shares
CY2021Q1 celz Performance Obligation And Payment
PerformanceObligationAndPayment
50000 usd
CY2021Q1 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
300000 usd

Files In Submission

Name View Source Status
0001477932-24-004635-index-headers.html Edgar Link pending
0001477932-24-004635-index.html Edgar Link pending
0001477932-24-004635.txt Edgar Link pending
0001477932-24-004635-xbrl.zip Edgar Link pending
celz-20240630.xsd Edgar Link pending
celz_10q.htm Edgar Link pending
celz_10qimg1.jpg Edgar Link pending
celz_ex311.htm Edgar Link pending
celz_ex312.htm Edgar Link pending
celz_ex321.htm Edgar Link pending
celz_ex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
celz-20240630_cal.xml Edgar Link unprocessable
celz-20240630_def.xml Edgar Link unprocessable
celz-20240630_lab.xml Edgar Link unprocessable
celz-20240630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
celz_10q_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending